Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Cytotherapy. 2021 May 9;23(7):627–634. doi: 10.1016/j.jcyt.2021.03.006

Table 4.

Summary of infusion reactions organized by toxicity endpoints of interest

Outcome All subjects (N=130)
Infusion reaction with any symptom, n (%)
 Yes 118 (90.8%)
 No 12 (9.2%)
Infusion reaction with any symptom, grade ≥ 3, n (%)
 Yes 37 (28.5%)
 No 93 (71.5%)
Cardiovascular reaction, grade ≥ 3, n (%)
 Yes 20 (15.4%)
 No 110 (84.6%)
Febrile reaction, grade 3, n (%)
 Yes 15 (11.5%)
 No 115 (88.5%)
Respiratory reaction, grade 3, n (%)
 Yes 8 (6.2%)
 No 122 (93.8%)
Headache, grade 3, n (%)
 Yes 8 (6.2%)
 No 122 (93.8%)
Headache, grade ≤ 3, n (%)
 Yes 29 (22.3%)
 No 101 (77.7%)